홈
마켓
차트 & 아이디어
Algo
뉴스
Store
브로커
다운로드
경제 달력
트레이딩 시그널
웹터미널
검색
/
타입: @user, $symbol
검색
로그인
계정을 생성하십시오
한국어
English
Русский
中文
Español
Português
日本語
Deutsch
Français
Italiano
Türkçe
PRLD
#2987
Prelude Therapeutics Incorporated
2.7
6
-5.80%
부문:
베이스:
수익 통화:
일일 변동 비율
년간 변동
일일 변동
-5.80%
월간 변동
+28.37%
6달 변화
+113.95%
년간 변동율
+253.85%
이전 종가
2.9
3
Open
2.7
6
Bid
Ask
Low
2.7
6
High
2.7
6
양
3
마켓
주식
헬스케어
PRLD
Open full chart
Financials
Overview
성명
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
TTM
Key stats
Total common shares outstanding
32.6 M
36.2 M
36.5 M
42.06 M
42.3 M
173.4 M
Valuation ratios
Enterprise value
3.11 B
561.19 M
209.92 M
198.24 M
57.85 M
124 M
Price to earnings ratio
—
—
-2.06
-2.01
-0.76
-2.7
Price to sales ratio
—
—
—
—
13.81
—
Price to cash flow ratio
—
—
-2.84
-2.29
-0.94
-3.15
Price to book ratio
—
—
1.22
1.04
0.74
1.26
Enterprise value to EBITDA ratio
—
—
—
—
—
—
Profitability ratios
Return on assets %
0.25
0.37
0.52
0.44
0.72
0.87
Return on equity %
0.27
0.39
0.59
0.51
0.97
1.28
Return on invested capital %
10.89 K
8 576.16
4 233.67
2 161.61
1 600.72
—
Gross margin %
100
—
—
—
100
—
Operating margin %
534.21 K
—
—
—
1 995.91
—
EBITDA margin %
—
—
—
—
—
—
Net margin %
517.54 K
—
—
—
1 816.76
—
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
19.41
15.37
9.42
10.79
5.3
17.36
Inventory turnover
—
—
—
—
—
—
Asset turnover
0
—
—
—
0.03
—
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
—
—
1.77
1.77
1.36
1.32
EBIT per share
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
—
—
7.87
7.3
1.76
4.75
Net current asset value per share
—
—
4.31
3.9
1.79
4.92
Tangible book value per share
—
—
4.13
3.93
1.73
4.86
Working capital per share
—
—
3.86
3.54
1.45
3.81
Book value per share
—
—
4.13
3.93
1.73
4.86
뉴스
프렐류드 테라퓨틱스, Citizens에서 ’시장 수익률 상회’ 등급 재확인
Prelude Therapeutics stock gets reiterated Market Outperform rating at Citizens
프렐루드 테라퓨틱스, FDA의 암 치료제 IND 승인 후 주가 급등
Prelude Therapeutics stock surges after FDA clears IND for cancer drug
Tracking Baker Brothers Portfolio – Q3 2025 Update (NASDAQ:INCY)
Prelude Therapeutics stock rating reiterated at Market Outperform by Citizens
Beat the Market the Zacks Way: Goldman Sachs, Micron, Prelude in Focus
프렐루드 테라퓨틱스, Citizens, ’시장수익률 상회’ 등급 재확인
Prelude Therapeutics stock rating reiterated at Market Outperform by Citizens
인사이트 코퍼레이션, 52주 신고가 경신… 108.81달러
프렐루드 테라퓨틱스 2025년 3분기 실적 발표: 주가 안정세 유지
Earnings call transcript: Prelude Therapeutics Q3 2025 sees stock steadiness